title: Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients.
abstract: Until now, less than 5% of the patients with breast ductal carcinoma in situ (DCIS) have been enrolled in clinical trials. Consequently, we have analysed the results of "current practice" among 716 women treated in eight French Cancer Centres from 1985 to 1992: 441 cases (61.6%) corresponded to impalpable lesions, 92 had a clinical size of less than or equal to 2 cm and 70 from 2 to 5 cm; in 113 cases, the size was unspecified. Median age was 53.2 years (range: 21-87 years). 145 patients underwent mastectomy (RS) and 571 conservative surgery (CS) without (136) or with (435) radiotherapy (CS+RT). The mean histological tumour sizes in these three groups were 25.6, 8.2, 14.8 mm, respectively (P<0.0001). After a 91-month median follow-up, local recurrence (LR) rates were 2.1, 30.1 and 13.8% in the RS, CS and CS +RT groups, respectively (P=0.001); LR were invasive in 59 and 60% in the CS and CS+RT groups, respectively. In these groups, the 8-year LR rates were 31.3 and 13.9%, respectively (P=0.0001). Nodal recurrence occurred in 3.7 and 1.8% in the CS and CS+RT groups. Metastases rates were 1.4, 4.4 and 1.4% in the RS, CS and CS+RT groups. Among the 60 cases of invasive LR, in CS and CS+RT groups 19% developed metastases. After multivariate analysis, we did not identify any significant LR risk factor in the CS group, whereas young age (<40 years) and incomplete excision were significant in the CS+RT group (P=0.012 and P=0.02, respectively).
authors.affiliation: Department of Radiotherapy, Centre Paul Strauss, Strasbourg, France. b.cutuli@wanadoo.fr
authors.forename: B
authors.initials: B
authors.lastname: Cutuli
authors.forename: C
authors.initials: C
authors.lastname: Cohen-Solal-Le Nir
authors.forename: B
authors.initials: B
authors.lastname: De Lafontan
authors.forename: H
authors.initials: H
authors.lastname: Mignotte
authors.forename: V
authors.initials: V
authors.lastname: Fichet
authors.forename: R
authors.initials: R
authors.lastname: Fay
authors.forename: V
authors.initials: V
authors.lastname: Servent
authors.forename: S
authors.initials: S
authors.lastname: Giard
authors.forename: C
authors.initials: C
authors.lastname: Charra-Brunaud
authors.forename: H
authors.initials: H
authors.lastname: Auvray
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: J C
authors.initials: JC
authors.lastname: Charpentier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000628:therapy*; D002278:Carcinoma in Situ / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors